2 weeks Ago By Defense World Staff
Teacher Retirement System of Texas lifted its holdings in Omnicell, Inc. ( NASDAQ:OMCL – Free Report ) by 59.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The institutional investor owned 26,682 shares of the company’s stock after purchasing an additional 9,896 shares during the quarter. Teacher Retirement System of Texas owned 0.06% of Omnicell worth $1,188,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the business. Smartleaf Asset Management LLC grew its stake in Omnicell by 51.5% in the fourth quarter.
Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares in the last quarter. Van ECK Associates Corp boosted its holdings in shares of Omnicell by 47.0% in the 4th quarter.
Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares during the last quarter. First Horizon Advisors Inc. grew its stake in shares of Omnicell by 36.
3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares in the last quarter.
KBC Group NV increased its holdings in Omnicell by 60.8% during the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares during the last quarter.
Finally, AlphaQuest LLC raised its position in Omnicell by 307.8% during the fourth quarter. AlphaQuest LLC now owns 3,576 shares of the company’s stock worth $159,000 after acquiring an additional 2,699 shares in the last quarter.
Institutional investors and hedge funds own 97.70% of the company’s stock. Analyst Ratings Changes A number of brokerages have recently commented on OMCL.
Benchmark reissued a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. JPMorgan Chase & Co.
lowered their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th.
Bank of America cut their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th.
StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a report on Monday, March 24th. Finally, Wells Fargo & Company cut their price target on Omnicell from $49.
00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company.
According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $51.00.
Omnicell Price Performance Shares of NASDAQ OMCL opened at $35.01 on Friday. The firm has a market cap of $1.
64 billion, a P/E ratio of 129.67, a price-to-earnings-growth ratio of 7.53 and a beta of 0.
85. The business’s 50 day moving average is $39.01 and its 200-day moving average is $42.
57. The company has a current ratio of 1.37, a quick ratio of 1.
22 and a debt-to-equity ratio of 0.13. Omnicell, Inc.
has a 1-year low of $25.12 and a 1-year high of $55.75.
Omnicell ( NASDAQ:OMCL – Get Free Report ) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.
57 by ($0.12). Omnicell had a return on equity of 3.
82% and a net margin of 1.13%. Equities research analysts predict that Omnicell, Inc.
will post 1.09 earnings per share for the current year. Omnicell Company Profile ( Free Report ) Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally.
The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. Featured Articles Five stocks we like better than Omnicell Why Invest in 5G? How to Invest in 5G Stocks MarketBeat Week in Review – 03/24 – 03/28 What Are Dividend Contenders? Investing in Dividend Contenders Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low High Flyers: 3 Natural Gas Stocks for March 2022 4 Healthcare Stocks With Massive Gains—and More to Come Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter .
.
